Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer: 10. Palliative care.

Literature DB >> 10065082

Prostate cancer: 10. Palliative care.

N A Iscoe¹, E Bruera, R C Choo.

Abstract

Entities: Disease

Mesh：

Year: 1999 PMID： 10065082 PMCID： PMC1230043

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

23 in total

1. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis.

Authors: P H Blitzer
Journal: Cancer Date: 1985-04-01 Impact factor: 6.860

2. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.

Authors: K Buchali; H J Correns; M Schuerer; D Schnorr; H Lips; K Sydow
Journal: Eur J Nucl Med Date: 1988

3. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report.

Authors: O M Salazar; P Rubin; F R Hendrickson; C Poulter; G Zagars; M I Feldman; S Asbell; L Doss
Journal: Int J Radiat Oncol Biol Phys Date: 1981-06 Impact factor: 7.038

4. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group.

Authors: D Tong; L Gillick; F R Hendrickson
Journal: Cancer Date: 1982-09-01 Impact factor: 6.860

5. Half body radiotherapy.

Authors: P J Fitzpatrick; W D Rider
Journal: Int J Radiat Oncol Biol Phys Date: 1976 Jan-Feb Impact factor: 7.038

6. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

Authors: A T Porter; A J McEwan; J E Powe; R Reid; D G McGowan; H Lukka; J R Sathyanarayana; V N Yakemchuk; G M Thomas; L E Erlich
Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-02 Impact factor: 7.038

7. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy X 6 versus 10 Gy X 2.

Authors: E L Madsen
Journal: Int J Radiat Oncol Biol Phys Date: 1983-12 Impact factor: 7.038

8. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.

Authors: P Price; P J Hoskin; D Easton; D Austin; S G Palmer; J R Yarnold
Journal: Radiother Oncol Date: 1986-08 Impact factor: 6.280

9. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases.

Authors: D J Cole
Journal: Clin Oncol (R Coll Radiol) Date: 1989-11 Impact factor: 4.126

10. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens.

Authors: M J Zelefsky; H I Scher; J D Forman; L A Linares; T Curley; Z Fuks
Journal: Int J Radiat Oncol Biol Phys Date: 1989-12 Impact factor: 7.038

9 in total

Prostate cancer: 10. Palliative care.

1. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis.

2. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.

3. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report.

4. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group.

5. Half body radiotherapy.

6. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

7. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy X 6 versus 10 Gy X 2.

8. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.

9. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases.

10. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens.

1. Prostate cancer from a patient's perspective.

2. Understanding obesity.

3. The more the better?

4. Understanding obesity.

5. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group.

6. Proof versus plausibility: rules of engagement for the struggle to evaluate alternative cancer therapies.

Review 7. Prostate cancer: 11. Alternative approaches and the future of treatment.

8. Discussing complementary therapies: there's more than efficacy to consider.

Review 9. Prostate cancer: 13. Whose prostate is it anyway? The view from the other side of the examining table.